CD274 and neoplasm: The 1-year OS rate in the virtual cohort of patients receiving chemotherapy will be estimated based on the KEYNOTE-024 and KEYNOTE-189 studies with a ratio between patients with a tumour PD-L1 expression <50% and ≥50% equal to that observed in our trial (Committee for medical products for human use CHMP, 2005).